Press Release

StreptaClick® HRP-based kit for tissue multiplexing with ZEISS Axioscan 7 spatial biology to be introduced

ZEISS partners with Kromnigon to launch multiplex IHC with 8 fluorescence channels using an accelerated heat-treatment-free TSA workflow

11 September 2025

Jena, Germany | 11 September 2025 | ZEISS Research Microscopy Solutions

Kromnigon and ZEISS partner to develop and launch a tailored StreptaClick^® HRP-based kit, specifically optimized for the ZEISS Axioscan 7 spatial biology automated slide scanner. This new kit targets the rapidly growing spatial biology market and delivers powerful multiplex immunofluorescence imaging of eight channels using Tyramide Signal Amplification (TSA).

"With StreptaClick^® HRP, researchers can combine the sensitivity of multiplex TSA without jeopardizing tissue morphology. The accelerated workflow without heat treatment makes it user-friendly at the lab bench as well as for autostainers", said Per Fogelstrand, CEO at Kromnigon.

Kromnigon’s proprietary HRP block buffer dramatically accelerates the iterative workflow by eliminating the need for heat treatment. This preserves tissue morphology, thereby reliably preventing epitope exhaustion – and uniquely enables TSA to be performed even on frozen tissues.

"ZEISS Axioscan 7 spatial biology is built for precision and high throughput. By integrating StreptaClick^® HRP, we can now provide our users with an even more powerful platform for analyzing multiple protein biomarkers simultaneously, without compromising image quality or tissue integrity", said Michael Albiez, Head of ZEISS Research Microscopy Solutions.

The unique combination of Kromnigon’s StreptaClick^® HRP technology and the advanced imaging capabilities of ZEISS Axioscan 7 spatial biology offers simultaneous detection of seven protein targets and a nuclear stain with improved preservation of tissue morphology and a faster workflow that can be completed in one day.

Press Contact Vybhav Sinha ZEISS Research Microscopy Solutions

About ZEISS

ZEISS is an internationally leading technology company in the optics and optoelectronics industry. The ZEISS Group generated annual revenue totaling around 11 billion euros in its four segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology (updated: 30 September 2024).

For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, as well as medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Industry 4.0 as well as a strong brand, ZEISS is shaping technological progress and, through its solutions, is extending the horizon of the world of optics and associated areas. ZEISS' significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 14% of its revenue in research and development work – ZEISS has a long tradition of high expenditure in these areas. This also represents the company's investment in the future.

With more than 46,555 employees, ZEISS operates in around 50 countries with more than 60 sales and service sites, 40 research and development sites and 35 production sites worldwide (as of 31 March 2025). The headquarters of the company, which was founded in Jena in 1846, is located in Oberkochen, Germany. The Carl Zeiss Foundation, one of Germany’s largest foundations committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

ZEISS Research Microscopy Solutions

ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA, China and Switzerland. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment.

Further information at www.zeiss.com/microscopy

About Kromnigon AB

Kromnigon is headquartered at the AstraZeneca BioVenture Hub in Mölndal, Sweden, and was founded in 2015 based on research at the University of Gothenburg. The company’s vision is to make multiplex immunohistochemistry seamless – through innovative staining reagents built on its patented StreptaClick^® technology and by advancing fluorochrome separation in microscopy with unique multi-bandpass filters.

At the core of the StreptaClick^® technology is an engineered streptavidin molecule that can be pre-mixed with biotinylated antibodies without causing aggregation. This capability makes StreptaClick^® workflows streamlined and highly flexible in designing antibody panels for both multiplex immunohistochemistry and flow cytometry. Kromnigon’s latest innovation, StreptaClick^® Precision, sets a new standard for precise conjugation of both small and large molecules to StreptaClick^®, such as fluorochromes, oligonucleotides, and lipid nanoparticles which can then be easily linked, along with their cargo, to a wide range of biotinylated antibodies.

The company name Kromnigon combines Krom – for colors, Omni – for many, and gon – from the Greek for “corner” in geometric figures. It reflects our mission: making multiplexing easy while maintaining scientific rigor.

Further information at https://kromnigon.com/